Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SARA SHELBY FRIEDMAN

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1649318569
CMS profile
979795
Location
ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$1,724.29

6 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,129.38 3
Food and Beverage $594.91 3

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
ModernaTX, Inc. $1,663.92 4
Merck Sharp & Dohme LLC $60.37 2

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SARA SHELBY FRIEDMAN

NPI 1649318569 · CMS profile ID 979795

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

ALBUQUERQUE, NM

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1649318569?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649318569?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649318569?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SARA SHELBY FRIEDMAN, NPI 1649318569, CMS profile ID 979795, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–6 of 6 matching records. This page contains 6 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1649318569?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

6 matching records · $1,724.29 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 6 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–6 of 6.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $25.3712/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048269819 CMS
Merck Sharp & Dohme LLC $35.0012/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048269817 CMS
ModernaTX, Inc. $534.5408/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056980807 CMS
ModernaTX, Inc. $572.8008/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056980843 CMS
ModernaTX, Inc. $206.7208/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056980859 CMS
ModernaTX, Inc. $349.8608/17/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1056980863 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $169.09 11
PY2023 $1,724.29 6
PY2024 $3,024.97 16

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2023, 2024
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2023 , PY2024
Generated from
OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,296,266.41 159
PY2024 Principal investigator $1,078,411.75 127
PY2023 Principal investigator $776,040.20 596
PY2022 Principal investigator $318,257.95 46

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

596 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $388.43 12/31/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, and Antiviral Activity of ABBV-903 in Non-Hospitalized Symptomatic Adults with Mild to Moderate COVID-19 No dispute reported 06/30/2026 998414211
Principal investigator 1 Merck Sharp & Dohme LLC $9,930.01 12/31/2023 Non-covered Recipient Entity
Velocity Clinical Research, Albuquerque
A Phase 3, Randomized, Placebo-Controlled, Double Blind Clinical Study to Evaluate the Efficacy and Safety of MK-4482 in Non-Hospitalized Adults with COVID-19 at High Risk for Disease Progression No dispute reported 06/30/2026 1042522565
Principal investigator 1 Merck Sharp & Dohme LLC $28,443.08 12/31/2023 Non-covered Recipient Entity
Velocity Clinical Research, Albuquerque
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety,Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Riskof Pneumococcal Disease No dispute reported 06/30/2026 1042565647
Principal investigator 1 Merck Sharp & Dohme LLC $533.33 12/31/2023 Non-covered Recipient Entity
Velocity Clinical Research, Albuquerque
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety,Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Riskof Pneumococcal Disease No dispute reported 06/30/2026 1061235868
Principal investigator 1 PFIZER INC. $1,900.00 12/27/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046031719
Principal investigator 1 ModernaTX, Inc. $99,122.49 12/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1040222029
Principal investigator 1 ModernaTX, Inc. $10,000.00 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1040202847
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1040202863
Principal investigator 1 ModernaTX, Inc. $2,000.00 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1040203001
Principal investigator 1 ModernaTX, Inc. $1,000.00 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1040203017
Principal investigator 1 PFIZER INC. $2,580.00 12/21/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046304431
Principal investigator 1 ModernaTX, Inc. $7,227.22 12/20/2023 Non-covered Recipient Entity
Velocity Clinical Research - Albuquerque - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042059935
Principal investigator 1 Bavarian Nordic A/S $12,350.20 12/14/2023 Non-covered Recipient Entity
Velocity Clinical Research
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988723853
Principal investigator 1 Bavarian Nordic A/S $850.80 12/13/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728135
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011125
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011133
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011139
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011143
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040011149
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040013645
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040013649
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040013657
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040016381
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040016387
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040016393
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040016787
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040016793
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040016801
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040019525
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040019536
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040019547
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040019559
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040025267
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040025279
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040025287
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040025299
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040029983
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040029991
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040030003
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040030013
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040030023
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040030033
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040030043
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040030055
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040034913
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040034923
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040034933
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040034943
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040034953
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040034963
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040040379
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040040389
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040040399
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040040411
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040040421
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040045055
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040050039
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040050051
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040050061
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056061
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056071
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056081
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056091
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040056101
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040059573
Principal investigator 1 ModernaTX, Inc. $480.63 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040059579
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040059585
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040059591
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040059599
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040065127
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040065137
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040065147
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040069933
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040069945
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040069953
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040069963
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040069975
Principal investigator 1 ModernaTX, Inc. $480.63 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040075393
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040075403
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040079745
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040084655
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040084663
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040090141
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040090151
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040090161
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040090169
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040090179
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040095041
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040095051
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040095061
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040095073
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040100063
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040100073
Principal investigator 1 ModernaTX, Inc. $480.63 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040100083
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040100093
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040100103
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040104899
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040104911
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040104923
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040104935
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040104947
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040110843
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040111692
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040111703
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040111717
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040117475
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040117485
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040124191
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040124203
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040124215
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040124227
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040124241
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040124253
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040124267
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040124281
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040129811
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040129823
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040129837
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040129849
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040129861
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040137165
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040137175
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040137188
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040137201
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040137213
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040137225
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040137235
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040137249
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040143197
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040143209
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040149231
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040149243
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040149255
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040149267
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040149279
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040149291
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040155435
Principal investigator 1 ModernaTX, Inc. $71.23 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040155447
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040155459
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040162175
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040162189
Principal investigator 1 ModernaTX, Inc. $176.62 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040162201
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040162209
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040162217
Principal investigator 1 ModernaTX, Inc. $480.63 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040167199
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040167211
Principal investigator 1 ModernaTX, Inc. $2.02 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040167223
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040167235
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040173255
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040173267
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040173281
Principal investigator 1 ModernaTX, Inc. $81.35 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040173291
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040173303
Principal investigator 1 ModernaTX, Inc. $206.17 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1040173317
Principal investigator 1 ModernaTX, Inc. $10,582.65 12/04/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
Phase 1/2a randomized, observer-blind, placebo-controlled, dose-ranging study of safety and immunogenicity of mRNA-1647 cytomegalovirus (CMV) vaccine in participants 9 to 15 years of age and open-label study of safety and immunogenicity of mRNA-1647 CMV vaccine in participants 9 to 25 years of age No dispute reported 06/30/2026 1040221689
Principal investigator 1 Mylan Inc. $8,900.00 11/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038727869
Principal investigator 1 ModernaTX, Inc. $100.00 11/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039973671
Principal investigator 1 ModernaTX, Inc. $5,483.27 11/17/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746663
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 11/16/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127787834
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 11/16/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127787838
Principal investigator 1 Bavarian Nordic A/S $1,500.00 11/07/2023 Non-covered Recipient Entity
Velocity Clinical Research
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988723829
Principal investigator 1 Bavarian Nordic A/S $750.00 11/07/2023 Non-covered Recipient Entity
Velocity Clinical Research
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988723865
Principal investigator 1 ModernaTX, Inc. $1,800.00 11/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1040206931
Principal investigator 1 ModernaTX, Inc. $9,516.00 11/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1040219037
Principal investigator 1 ModernaTX, Inc. $2,000.00 11/01/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 3, randomized, observerblind, activecontrol study to evaluate the safety, reactogenicity, and immunogenicity of mRNA1083 (SARSCoV2 and influenza) vaccine in healthy adult participants, 50 years of age. No dispute reported 06/30/2026 1040223955
Principal investigator 1 ModernaTX, Inc. $66.24 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Children 2 to <18 Years of Age at High Risk of Respiratory Syncytial Virus Disease No dispute reported 06/30/2026 1039784997
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039916139
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039916153
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039916167
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039916181
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039916193
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039916205
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039916219
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039918921
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039918933
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039918947
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039918961
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039918974
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039918987
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039919001
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039919017
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039921121
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039921134
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039921147
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039921161
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039922404
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039922421
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039922433
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039922445
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039922459
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039924435
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039924447
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039924461
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039924475
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039924489
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039924503
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039926261
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039926275
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039926289
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039926303
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039926315
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039926329
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039928681
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039929903
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039929913
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039929923
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039929933
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039931411
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039931421
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039931431
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039931439
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933183
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933191
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933203
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933213
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933225
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933233
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933243
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039933253
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039934309
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039934319
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039934325
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039934333
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039934343
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039934351
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039934361
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039934371
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039935965
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039935977
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039935989
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039936001
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039936013
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039936023
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039936035
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039937825
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039937835
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039937845
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039937855
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039937865
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039937873
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039937883
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039937893
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039939709
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039939719
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039939729
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039939739
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039939749
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039941273
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039941283
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039941293
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039941303
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039941315
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039942705
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039942715
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039942723
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039942733
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039942743
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944105
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944115
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944125
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039944135
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945107
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945117
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945127
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945137
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945145
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039945759
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039946513
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039946523
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039946533
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039946543
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039947165
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039948867
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039948873
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039948879
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039948885
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039948891
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039949685
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039949691
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039949697
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039949703
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039949709
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950941
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950947
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950953
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950959
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950965
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950971
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950977
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950985
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950991
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039950999
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039951003
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039951845
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039951853
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039951859
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039951865
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039952581
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039952587
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039952593
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039952599
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953677
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953683
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953689
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953695
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039953701
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954669
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954675
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954681
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954689
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954695
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039954701
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955319
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955325
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955331
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955337
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955343
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955349
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039955355
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039956443
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039956449
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039956455
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039956461
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039956469
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039956473
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957329
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957335
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957341
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957347
Principal investigator 1 ModernaTX, Inc. $732.16 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957353
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957359
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957365
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957371
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957377
Principal investigator 1 ModernaTX, Inc. $4,325.67 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957383
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039957389
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039958249
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039958257
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039958263
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039958269
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039958275
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959065
Principal investigator 1 ModernaTX, Inc. $641.03 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959071
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959077
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959083
Principal investigator 1 ModernaTX, Inc. $1,855.52 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959089
Principal investigator 1 ModernaTX, Inc. $18.23 10/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039959095
Principal investigator 1 ModernaTX, Inc. $5,099.31 10/13/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746609
Principal investigator 1 GlaxoSmithKline, LLC. $1,497.87 10/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127787830
Principal investigator 1 Bavarian Nordic A/S $6,739.20 10/10/2023 Non-covered Recipient Entity
Velocity Clinical Research
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988723841
Principal investigator 1 ModernaTX, Inc. $10,558.35 10/06/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1041746657
Principal investigator 1 Mylan Inc. $167.00 10/06/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1038728103
Principal investigator 1 Bavarian Nordic A/S $1,000.00 10/03/2023 Non-covered Recipient Entity
Velocity Clinical Research
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988723859
Principal investigator 1 PFIZER INC. $400.00 09/30/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046016757
Principal investigator 1 ModernaTX, Inc. $5,695.82 09/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746501
Principal investigator 1 PFIZER INC. $9,850.00 09/20/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046235893
Principal investigator 1 ModernaTX, Inc. $600.00 08/30/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039858053
Principal investigator 1 ModernaTX, Inc. $2,500.00 08/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039856855
Principal investigator 1 ModernaTX, Inc. $11,000.00 08/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039856869
Principal investigator 1 ModernaTX, Inc. $2,500.00 08/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039858747
Principal investigator 1 ModernaTX, Inc. $1,200.00 08/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039858765
Principal investigator 1 ModernaTX, Inc. $1,000.00 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040204753
Principal investigator 1 ModernaTX, Inc. $1,500.00 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040206871
Principal investigator 1 ModernaTX, Inc. $6,500.00 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040216611
Principal investigator 1 ModernaTX, Inc. $800.00 08/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040223919
Principal investigator 1 ModernaTX, Inc. $4,329.91 08/23/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746405
Principal investigator 1 PFIZER INC. $170.10 08/22/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046038947
Principal investigator 1 PFIZER INC. $510.30 08/17/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046224915
Principal investigator 1 ModernaTX, Inc. $13,564.00 08/16/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746399
Principal investigator 1 Bavarian Nordic A/S $1,263.60 08/10/2023 Non-covered Recipient Entity
Velocity Clinical Research
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988723835
Principal investigator 1 ModernaTX, Inc. $3,246.90 08/10/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039855439
Principal investigator 1 PFIZER INC. $170.10 08/09/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046230091
Principal investigator 1 ModernaTX, Inc. $5,143.91 08/04/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746393
Principal investigator 1 Bavarian Nordic A/S $6,759.00 08/01/2023 Non-covered Recipient Entity
Velocity Clinical Research
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988723847
Principal investigator 1 Bavarian Nordic A/S $1,500.00 08/01/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727583
Principal investigator 1 Bavarian Nordic A/S $750.00 08/01/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728141
Principal investigator 1 Bavarian Nordic A/S $1,000.00 08/01/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728153
Principal investigator 1 Bavarian Nordic A/S $500.00 08/01/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728161
Principal investigator 1 PFIZER INC. $170.10 07/26/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046328591
Principal investigator 1 ModernaTX, Inc. $3,500.00 07/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age No dispute reported 06/30/2026 1040214011
Principal investigator 1 PFIZER INC. $6,318.00 07/19/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046219605
Principal investigator 1 GlaxoSmithKline, LLC. $6,646.86 07/18/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127787840
Principal investigator 1 ModernaTX, Inc. $2,670.04 07/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years No dispute reported 06/30/2026 1040205471
Principal investigator 1 ModernaTX, Inc. $11,461.07 07/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746387
Principal investigator 1 Bavarian Nordic A/S $862.20 07/04/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727607
Principal investigator 1 PFIZER INC. $170.10 06/29/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046085131
Principal investigator 1 Bavarian Nordic A/S $1,053.00 06/28/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728117
Principal investigator 1 Bavarian Nordic A/S $4,500.00 06/28/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728147
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127787828
Principal investigator 1 GlaxoSmithKline, LLC. $9,000.00 06/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127787832
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127787836
Principal investigator 1 Bavarian Nordic A/S $1,263.60 06/20/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727689
Principal investigator 1 PFIZER INC. $1,530.90 06/16/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046313455
Principal investigator 1 ModernaTX, Inc. $11,177.68 06/14/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746381
Principal investigator 1 PFIZER INC. $680.40 06/14/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046143309
Principal investigator 1 Bavarian Nordic A/S $1,053.00 06/13/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727645
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788131
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788139
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788147
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788157
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788165
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788173
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788183
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788191
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788199
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788207
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788215
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788223
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788231
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788239
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788247
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788255
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788263
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788271
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788279
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788287
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788295
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788303
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788311
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788319
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788327
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788337
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788345
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788353
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788363
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788371
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788379
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788387
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788395
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788403
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788411
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788419
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788427
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788435
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788443
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788451
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788459
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788467
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788475
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788483
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788491
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788499
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788509
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788517
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788525
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788533
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788541
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788549
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788557
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788565
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788573
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788581
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788589
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788597
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788605
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788613
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788621
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788629
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788637
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788645
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788653
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788661
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788669
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788677
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788687
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788693
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788701
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788713
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788719
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788727
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788737
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788745
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788753
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788761
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788769
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788777
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788785
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788793
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788801
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788809
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788817
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788825
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788833
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788841
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788849
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788857
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788865
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788873
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788883
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788891
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788900
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788907
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788915
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788923
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788929
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788939
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788947
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788955
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788963
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788971
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788979
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788987
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039788995
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789003
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789011
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789019
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789027
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789035
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789045
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789051
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789061
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789069
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789077
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789085
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789093
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789101
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789109
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789117
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789125
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789133
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789141
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789147
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789155
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789163
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789171
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789179
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789187
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789195
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789203
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789211
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789219
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789227
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789235
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789243
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789251
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789259
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789267
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789275
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789283
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789293
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789301
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789309
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789317
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789325
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789333
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789341
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789349
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789357
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789365
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789373
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789381
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789389
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789397
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789405
Principal investigator 1 ModernaTX, Inc. $4,325.67 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789413
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789421
Principal investigator 1 ModernaTX, Inc. $732.16 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789429
Principal investigator 1 ModernaTX, Inc. $18.23 06/12/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1039789437
Principal investigator 1 Bavarian Nordic A/S $1,825.20 06/08/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727619
Principal investigator 1 PFIZER INC. $3,061.80 06/03/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046316139
Principal investigator 1 Bavarian Nordic A/S $842.40 05/30/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728129
Principal investigator 1 PFIZER INC. $510.30 05/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046118985
Principal investigator 1 Bavarian Nordic A/S $491.40 05/19/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727675
Principal investigator 1 Bavarian Nordic A/S $1,333.80 05/16/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727665
Principal investigator 1 Bavarian Nordic A/S $772.20 05/09/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727633
Principal investigator 1 Bavarian Nordic A/S $912.60 05/03/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727595
Principal investigator 1 ModernaTX, Inc. $7,962.05 05/03/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746369
Principal investigator 1 ModernaTX, Inc. $43.16 04/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041745557
Principal investigator 1 Bavarian Nordic A/S $1,333.80 04/26/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728111
Principal investigator 1 PFIZER INC. $4,400.00 04/21/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046129027
Principal investigator 1 Bavarian Nordic A/S $2,246.40 04/18/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727669
Principal investigator 1 Bavarian Nordic A/S $1,283.40 04/13/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727639
Principal investigator 1 ModernaTX, Inc. $150.00 04/13/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1041745551
Principal investigator 1 PFIZER INC. $5,340.20 04/05/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046031705
Principal investigator 1 Bavarian Nordic A/S $2,406.60 04/04/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727601
Principal investigator 1 Bavarian Nordic A/S $421.20 03/29/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728123
Principal investigator 1 ModernaTX, Inc. $5,250.12 03/24/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746363
Principal investigator 1 Bavarian Nordic A/S $1,895.40 03/21/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728089
Principal investigator 1 Bavarian Nordic A/S $3,993.30 03/15/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727651
Principal investigator 1 PFIZER INC. $680.40 03/09/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046298303
Principal investigator 1 PFIZER INC. $170.10 03/07/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1045963857
Principal investigator 1 PFIZER INC. $3,742.20 03/04/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046300091
Principal investigator 1 ModernaTX, Inc. $8,503.05 03/01/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041746357
Principal investigator 1 Bavarian Nordic A/S $2,196.00 02/22/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728097
Principal investigator 1 PFIZER INC. $10,207.35 02/18/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046100461
Principal investigator 1 Bavarian Nordic A/S $3,268.80 02/16/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727657
Principal investigator 1 GlaxoSmithKline, LLC. $2,678.60 02/10/2023 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE 1/2, RANDOMIZED, OBSERVER-BLINDED, MULTI-COUNTRY STUDY TO EVAL No dispute reported 06/30/2026 1006246789
Principal investigator 1 PFIZER INC. $3,814.29 02/10/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046042209
Principal investigator 1 Bavarian Nordic A/S $1,283.40 02/09/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727627
Principal investigator 1 PFIZER INC. $4,150.98 02/07/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046125077
Principal investigator 1 Bavarian Nordic A/S $1,185.30 02/02/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727589
Principal investigator 1 ModernaTX, Inc. $376.68 01/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH- NEW MEXICO
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1041745605
Principal investigator 1 Bavarian Nordic A/S $6,529.50 01/25/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988728103
Principal investigator 1 Bavarian Nordic A/S $1,283.40 01/20/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727681
Principal investigator 1 PFIZER INC. $2,585.79 01/12/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 3 RANDOMIZED OBSERVERBLINDED STUDY TO EVALUATE THE EFFICACY SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MODIFIED RNA VACCINE AGAINST INFLUENZA COMPARED TO LICENSED INACTIVATED INFLUENZA VACCINE IN HEALTHY ADULTS 18 YEARS OF AGE OR OLDER No dispute reported 06/30/2026 1046351057
Principal investigator 1 Bavarian Nordic A/S $5,728.50 01/06/2023 Non-covered Recipient Entity
Med Pharmics, LLC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988727613